104010-92-6

Usage

Uses

Used in Pharmaceutical Industry:
D,L-N,N'-Di-tert-butoxycarbonyl-2,3-diaminopropionic acid is used as a building block for the synthesis of peptides and peptoids for the development of potential drug candidates. The Boc protecting group allows for selective deprotection and controlled assembly of specific peptide sequences, which is crucial for the creation of bioactive molecules with therapeutic potential.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, D,L-N,N'-Di-tert-butoxycarbonyl-2,3-diaminopropionic acid is used as a key component in the synthesis of complex peptide structures. Its ability to prevent unwanted reactions and enable selective deprotection makes it an indispensable tool for researchers working on the design and development of novel therapeutic agents.
Used in Peptide Synthesis:
D,L-N,N'-Di-tert-butoxycarbonyl-2,3-diaminopropionic acid is used as a protected amino acid in peptide synthesis. The Boc protecting group ensures that the amine groups remain unreactive during the synthesis process, allowing for the controlled addition of other amino acids to form the desired peptide sequence. This selective protection and deprotection process is vital for the successful synthesis of peptides with specific biological activities.

Upstream product

• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 54897-59-5 2,3-diaminopropanoic acid hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 515-94-6 2,3-diaminopropanoic acid 
• 18635-45-5 D,L-α,β-diaminopropionic acid monohydrobromide 
• 109461-78-1 ethyl 2,3-bis[(tert-butoxycarbonyl)amino]propionate 

Downstream Products

• 109273-25-8 2,3-di(butyloxycarbonylamino)propionic acid benzyl ester 
• 225115-99-1 ({3-(2-{2-[2-(2,3-bis-tert-butoxycarbonylamino-propionylamino)-ethoxy]-ethoxy}-ethylcarbamoyl)-5-[(bis-ethoxycarbonylmethyl-amino)-methyl]-benzyl}-ethoxycarbonylmethyl-amino)-acetic acid ethyl ester 
• 113647-56-6 [2-tert-Butoxycarbonylamino-3-oxo-3-(4-phenyl-piperidin-1-yl)-propyl]-carbamic acid tert-butyl ester 
• 1443511-07-6 4β-N-[2'',3''-bis (tert-butoxycarbonylamino)propanoyl]-podophyllotoxin 
• 1443511-08-7 4β-N-[2'',3''-bis(tert-butoxycarbonylamino)propanoyl]-4'-O-demethyl-podophyllotoxin 
• 1607465-16-6 N,N-di-tert-butoxycarbonyl[N-(2-N-acetylamino-4-(3-aminophenyl)thiazole)]-2,3-diaminopropanamide 
• 1312306-37-8 (R,S)-N-benzyl 2,3-bis(t-butoxycarbonylamino)propionamide 

Relevant academic research and scientific papers

Selective and monofunctional guanosine 5′-monophosphate binding by chloro[3-(2,3-diaminopropionylamino)propionic acid]-(dimethyl sulfoxide)platinum(II) complex

A new complex of chloro[3-(2,3-diaminopropionylamino)propionic acid](dimethyl sulfoxide)platinum(II) ([PtCl-(dmso)(Hdapap)]CF 3CO2·2H2O) was synthesized and characterized. Among a series of nucleic acids, the selective and 1:1 binding between [PtCl(dapap)(dmso)] and a guanosine 5′-monophosphate ion (Hgmp-) in an aqueous solution at pH 4.0 (20 mmol dm-3, each) was achieved by conducting ESI-MS and NMR experiments. This reaction included the initial chloride ion displacement by H2O, followed by metal coordination to the NT-position of the guanine base. The latter step was not affected in the case of guanosine-3′,5′-cyclic monophosphate ion (cgmp-), indicating that the phosphate-Pt binding can be ruled out in this system. In order to monitor the binding reaction of [PtCl(dapap)(dmso)] with several nucleic acids, time-course 1H and 31PNMR experiments were performed at 25 °C. Changes in the NMR chemical shifts of H8, H1′, and phosphate signals in Hgmp- upon the addition of [PtCl(dapap)(dmso)] revealed that two products finally remained. Since the synthetic dapap ligand could regulate the reactivity of a ligand coordinated to the Pt-center in [PtCl(dapap)(dmso)], this may arise from the presence of cis- and trans-isomers of [PtCl(dapap)-(dmso)] in solution.

Manganese Complex of Ethylenediaminetetraacetic Acid (EDTA)-Benzothiazole Aniline (BTA) Conjugate as a Potential Liver-Targeting MRI Contrast Agent

A novel manganese(II) complex based on an ethylenediaminetetraacetic acid (EDTA) coordination cage bearing a benzothiazole aniline (BTA) moiety (Mn-EDTA-BTA) was designed and synthesized for use as a liver-specific MRI contrast agent with high chelation stability. In addition to forming a hydrophilic, stable complex with Mn2+, this new Mn chelate was rapidly taken up by liver hepatocytes and excreted by the kidneys and biliary system. The kinetic inertness and R1 relaxivity of the complex were much higher than those of mangafodipir trisodium (MnDPDP), a clinically approved liver-specific MRI contrast agent. The diagnostic utility of this new Mn complex in MRI was demonstrated by high-sensitivity tumor detection in an animal model of liver cancer.

Synthesis and Evaluation of Manganese(II)-Based Ethylenediaminetetraacetic Acid-Ethoxybenzyl Conjugate as a Highly Stable Hepatobiliary Magnetic Resonance Imaging Contrast Agent

In this study, we designed and synthesized a highly stable manganese (Mn2+)-based hepatobiliary complex by tethering an ethoxybenzyl (EOB) moiety with an ethylenediaminetetraacetic acid (EDTA) coordination cage as an alternative to the well-established hepatobiliary gadolinium (Gd3+) chelates and evaluated its usage as a T1 hepatobiliary magnetic resonance imaging (MRI) contrast agent (CA). This new complex exhibits higher r1 relaxivity (2.3 mM-1 s-1) than clinically approved Mn2+-based hepatobiliary complex Mn-DPDP (1.6 mM-1 s-1) at 1.5 T. Mn-EDTA-EOB shows much higher kinetic inertness than that of clinically approved Gd3+-based hepatobiliary MRI CAs, such as Gd-DTPA-EOB and Gd-BOPTA. In addition, in vivo biodistribution and MRI enhancement patterns of this new Mn2+ chelate are comparable to those of Gd3+-based hepatobiliary MRI CAs. The diagnostic efficacy of the new complex was demonstrated by its enhanced tumor detection sensitivity in a liver cancer model using in vivo MRI.

Phenalenyl based platinum anticancer compounds with superior efficacy: design, synthesis, characterization, and interaction with nuclear DNA

Significant efforts have been made to develop new platinum anticancer compounds since the discovery ofcis-platin; however, non-specific toxicity or loss of efficacy remain some of the major challenges in this area of platinum drug discovery. Newly developed platinum compounds, structurally distinct from the current molecules, imparting efficacy at lower concentrations than the current drugs, and interacting with DNA leading to cell death, may prove beneficial. In the current study, we designed, synthesized, and characterized three phenalenyl based platinum chloride compounds (1,2, and3) with the goal that a labile Pt-Cl bond with the planar structure of the phenalenyl moiety would enhance their interaction with DNA, leading to improved efficacy. In addition, it is assumed that the fluorescent properties of these compounds would facilitate mechanistic investigation. The crystal structure of compound1demonstrates a perfectly planar structure with a single Pt-Cl bond.In vitrocell viability studies on cancer cell lines, including lung, colorectal, breast, and osteosarcoma, revealed a superior efficacy for compounds1and2, relative to platinum drugs in clinical use. Localization studies utilized the strong fluorescence of compound3to investigate the mechanism of action, revealing its interaction with DNA, leading to cell death. This study enriches the arsenal of potential platinum-based anti-cancer therapeutics and provides an easy-to-use tool for the mechanism-of-action studies of these compounds.

COMPOUND HAVING NOVEL STRUCTURE, COMPLEX COMPRISING SAME, ANTI-CANCER PHARMACEUTICAL COMPOSITION, AND ANTI-CANCER DRUG

The present invention relates to a compound, a complex comprising same, an anti-cancer pharmaceutical composition, and an anti-cancer drug. The compound of the present invention has the structure represented by chemical formula 1 of the present invention.

Synthesis, characterization, and anticancer activity of benzothiazole aniline derivatives and their platinum (Ii) complexes as new chemotherapy agents

We describe the synthesis, characterization, molecular modeling, and in vitro anticancer activity of three benzothiazole aniline (BTA) ligands and their corresponding platinum (II) complexes. We designed the compounds based on the selective antitumor properties of BTA, along with three types of metallic centers, aiming to take advantage of the distinctive and synergistic activity of the complexes to develop anticancer agents. The compounds were characterized using nuclear magnetic resonance spectrometry, Fourier transform infrared spectroscopy, mass spectrometry, elemental analysis, and tested for antiproliferative activity against multiple normal and cancerous cell lines. L1, L2, and L1Pt had better cytotoxicity in the liver, breast, lung, prostate, kidney, and brain cells than clinically used cisplatin. Especially, L1 and L1Pt demonstrated selective inhibitory activities against liver cancer cells. Therefore, these compounds can be a promising alternative to the present chemotherapy drugs.

SPHINGOSINE ANALOGS AND USE THEREOF AGAINST BACTERIAL LUNG INFECTIONS

Provided herein is a group of sphingosine analogs, useful in the treatment of bacterial infections in mucosal surfaces such as lungs, caused by pathogenic bacteria which are typical to disorders and diseases such as CF and COPD.

Progesterone-pyrazinamide compound, preparation method and anti-cancer application thereof

The invention discloses a progesterone-pyrazinamide compound, a preparation method and anti-cancer application thereof. The general structural formula of the compound is shown as a formula (I). The preparation method disclosed by the invention includes: carrying out Boc amino protection, amidation and Boc removal reaction to obtain an amino acid molecular fragment 3a-o; conducting progesterone C-20 carbonyl protection, A ring C-4 site dimethyl introduction and C-2 oxidation to synthesize an intermediate 6 containing 2, 3-o-dicarbonyl; and finally, constructing a pyrazine ring by utilizing diamino of an amino acid fragment and steroid A ring o-dicarbonyl so as to obtain a target molecule. The progesterone-pyrazinamide compound provided by the invention has inhibitory activity on breast cancer, liver cancer and prostate cancer, and especially has more remarkable inhibitory activity on prostate cancer cells.

HUMAN TOPOISOMERASE II-TARGETING ORGANOPLATINUM COMPOUNDS

Some organoplatinum compounds have been synthesized. These organoplatinum compounds are designed to be human Topoisomerase II-targeting drugs.

ORGANOPLATINUM COMPOUNDS AND PHARMACEUTICAL COMPOSITION THEREOF AND METHOD OF PREPARING CRYSTAL OF hTop2

Some organoplatinum compounds have been synthesized. These organoplatinum compounds are designed to be human Topoisomerase II-targeting drugs.